Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. (APRE) reported a net loss of $12.6 million for FY 2025, an improvement from $13.0 million in FY 2024, driven by reduced operating expenses to $13.5 million from $15.8 million, despite grant revenue declining to $286K from $1.5 million. Research and development expenses fell to $7.0 million from $9.4 million, while general and administrative held steady at $6.5 million. Loss from operations narrowed to $13.2 million from approximately $14.3 million. Cash used in operations was $12.9 million, with net cash provided by financing of $4.6 million, resulting in an $8.3 million decrease in cash, cash equivalents, and restricted cash to $21.6 million. Balance sheet shows $15.9 million total assets, including $14.6 million cash, and $12.4 million stockholders' equity. EPS improved to -$1.93 from -$2.35. The company faces going concern doubts with cash insufficient for 12 months, advancing APR-1051 Phase 1 trial with early proof-of-concept and pausing ATRN-119 monotherapy for combinations. Strategic focus on synthetic lethality oncology pipeline amid liquidity challenges.

Key Takeaways